Acute Radiation Syndrome - Pipeline Insight, 2020

Posted January 28, 2021 by Vidhyanigam98

This segment of the Acute Radiation Syndrome report encloses its detailed

Bharat Book Bureau Provides the Treding Market Research Report on "Acute Radiation Syndrome - Pipeline Insight, 2020" under Life Sciences Category. The report offers a collection of superior market researach, market analysis, competitive intelligence and Market reports.

“Acute Radiation Syndrome - Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Acute Radiation Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Acute Radiation Syndrome Understanding
Acute Radiation Syndrome: Overview

Request a Free Sample Copy Global Acute Radiation Syndrome Market [email protected]

Acute Radiation Syndrome (ARS) also known as radiation toxicity or radiation sickness is an illness when a person’s whole body or a significant portion of body is exposed to high levels of radiation for a short period of time. The amount of radiation that a person’s body absorbs is called the radiation dose. The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Types of radiation that can cause ARS include alpha radiation particles, beta radiation particles - charged particles (electrons), gamma rays, x-rays, neutrons etc.

The effects of exposure to radiations are nonspecific signs and symptoms such as nausea, emesis, fatigue, fever, Diarrhea, Headache, Dizziness and disorientation, Hair loss, Bloody vomit and stools from internal bleeding, low blood pressure and anorexia. The severity of symptoms depends on how much radiation was absorbed, the strength of the radiated energy, the time of exposure, and the distance between body and the source of radiation. The severity of radiation sickness also depends on sensitivity of the affected tissue like the gastrointestinal system and bone marrow are highly sensitive to radiation.

A diagnosis of Acute Radiation Syndrome without any history of exposure to radiation is complicated as the symptoms are nonspecific. The quickest and easiest laboratory test to provide an estimate of exposure is by measuring an absolute lymphocyte count is. Cytogenetic dosimetry, the gold standard, relies on predictable and standardized effects of radiation on deoxyribonucleic acid (DNA) replication in cultured lymphocytes.

Treatment of Acute Radiation Syndrome (ARS) focuses on reducing and treating infections, maintaining hydration, and treating injuries and burns, surgery for patients with life threatening disease. Some patients may benefit from treatments that help the bone marrow recover its function. Supportive care saves lives when it comes to acute radiation syndrome. The lower the radiation dose, the more likely it is that the person will recover from ARS. For survivors of ARS, the recovery process may last from several weeks up to 2 years. Prevention of thyroid cancer must be a priority. All children and pregnant women must be offered potassium iodide to protect the thyroid from the uptake of radioactive iodine.

Acute Radiation Syndrome Emerging Drugs Chapters
This segment of the Acute Radiation Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Radiation Syndrome Emerging Drugs
• HemaMax: Neumedicines
HemaMax™ is based on recombinant human interleukin-12 (IL-12) and is a broad-spectrum biologic therapy. IL-12 is a heterodimeric cytokine that has been shown to play an essential role in regulating inflammatory responses, including an innate resistance to infection and an ability to stimulate the production of interferon-gamma from natural killer cells, macrophages and T-cells. IL-12 also has shown resistance to many pathogens and to transplantable and chemically induced tumors.
• Recilisib: Onconova Therapeutics
Recilisib is a protein kinase inhibitor based small molecule with radiation protection properties. It addresses the need for medical countermeasures to treat the effects of acute radiation syndromes (ARS), specifically radiation-induced cytopenia. Recilisib employs a novel mechanism of action that involves intracellular signaling and DNA damage repair pathways. In pre-clinical studies, cells treated with Recilisib sustained less DNA damage upon exposure to ionizing radiation in comparison to untreated cells.

Browse our full report with Table of content:

About Bharat Book Bureau:
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 12,00,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts, Customized Intelligence, Newsletters and Online Databases, Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.

Contact us at:
Bharat Book Bureau
Tel: +912227810772 / 27810773
Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Vidhya Nigam
Phone 02227810772
Business Address 808, Real Tech Park, 8th Floor, Sector -
30A, Vashi, Navi Mumbai - 400703, India.
Country India
Categories Science
Tags acute radiation syndrome market , acute radiation syndrome market report , acute radiation syndrome market research report
Last Updated January 28, 2021